Immunovant (IMVT) Return on Capital Employed (2019 - 2026)
Immunovant (IMVT) reported Return on Capital Employed of 56.14% for Q1 2026, up 2181.0% on a YoY basis from 2.46% in Q1 2025, and up 8.41% quarter-over-quarter from 61.29% in Q4 2025.
Immunovant (IMVT) Return on Capital Employed (2019 - 2026) Analysis & Trends
Immunovant has reported Return on Capital Employed for 8 years, with the latest figure at 56.14% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2181.0% year-over-year to 56.14%; the trailing twelve-month figure through Mar 2026 stood at 56.14% (up 2181.0% YoY), and the FY2026 full-year result was 66.31%, down 302.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 56.14%, up from 61.29% in the prior quarter.
- The five-year high for Return on Capital Employed was 32.34% in Q1 2022, with the low at 95.54% in Q4 2024.
- Historically, Return on Capital Employed has averaged 60.36% across 5 years, with a median of 56.14% in 2026.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 4795 bps — and 2025, when it jumped 3425 bps.
- Immunovant's Return on Capital Employed stood at 49.31% in 2022, then decreased by 5 bps to 51.98% in 2023, then sank by 84 bps to 95.54% in 2024, then surged by 36 bps to 61.29% in 2025, then advanced by 8 bps to 56.14% in 2026.
- The last three Return on Capital Employed figures came in at 56.14% (Q1 2026), 61.29% (Q4 2025), and 82.74% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | -56.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.14% |
| Dec 31, 2025 | -61.29% |
| Sep 30, 2025 | -82.74% |
| Jun 30, 2025 | -66.91% |
| Mar 31, 2025 | -77.94% |
| Dec 31, 2024 | -95.54% |
| Sep 30, 2024 | -66.40% |
| Jun 30, 2024 | -46.64% |
| Mar 31, 2024 | -40.41% |
| Dec 31, 2023 | -51.98% |
| Sep 30, 2023 | -90.77% |
| Jun 30, 2023 | -74.85% |
| Mar 31, 2023 | -54.40% |
| Dec 31, 2022 | -49.31% |
| Sep 30, 2022 | -42.82% |
| Jun 30, 2022 | -35.70% |
| Mar 31, 2022 | -32.34% |
| Dec 31, 2021 | -26.58% |
| Sep 30, 2021 | -28.65% |
| Jun 30, 2021 | -29.40% |